This COVID-Era Biotech Favorite Is Surging Once Again On Strong Q4 Guidance: Momentum Score Spikes
I'm PortAI, I can summarize articles.
Massachusetts-based Moderna Inc. (NASDAQ:MRNA) is experiencing a resurgence with a significant increase in its Momentum score, rising from 22.5 to 74.61 in just a week. The stock has climbed 76% from its November 2025 lows, driven by a better-than-expected revenue outlook of $1.9 billion for 2025 and a $200 million reduction in operating expenses. Despite a recent 3.01% decline, shares are up 0.66% overnight, reflecting renewed investor optimism.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments